Theriva Biologics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.39M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.45 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-6.81 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | Before market open | – | – | – |
Press releases
Announcements Theriva Biologics filed with the SEC
Theriva™ Biologics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Theriva™ Biologics Announces First Patient
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Announces Results from
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Reports First Quarter 2026 Operational Highlights
Results of operations · EX-99.1 to Form 8-K
Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CT162: Analysis of tumor and biomarker responses in the VIRAGE trial, a randomized phase IIb, open-label, study of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Reports Full-Year 2025 Operational Highlights
Results of operations · EX-99.1 to Form 8-K
Theriva™ Biologics Licenses SYN-020 to
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Unique Oncolytic Virus Therapies for Multiple Solid Tumors January 2026
Other events · EX-99.1 to Form 8-K
Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
European Society for Medical Oncology (ESMO) Via Ginevra 4, CH - 6900 Lugano T. +41 (0)91 973 19 00 [email protected] esmo.org
Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Announces a Warrant
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
2b trial to be presented at ESMO 2025 -
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Honoraria, shares and funding from Theriva Biologics.
Other events · EX-99.1 to Form 8-K
Describing Next Generation Oncolytic Adenovirus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports First Quarter
Results of operations · EX-99.1 CHARTER to Form 8-K
Theriva Biologics Announces Pricing of $7.5
Material agreement · Other events · EX-99.1 to Form 8-K
Theriva Biologics Announces Closing of $7.5
Material agreement · Other events · EX-99.2 to Form 8-K
Theriva™ Biologics Announces Primary Endpoints
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VIRAGE Phase 2b Clinical Trial of VCN - 01 in Pancreatic Cancer 07 May 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports Full-Year 2024
Results of operations · EX-99.1 to Form 8-K
Theriva™ Biologics Announces U.S. FDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Theriva Biologics Announces Orphan Medicinal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva Biologics Announces Pricing of $2.5
Material agreement · Other events · EX-99.1 to Form 8-K
VCN - 01 IN PANCREATIC CANCER
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Achieves Target Patient
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Funding from the Spanish Government’s National Knowledge Transfer Program
New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva Biologics Announces Reverse Stock
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Theriva™ Biologics Receives Rare Pediatric
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Theriva™ Biologics Announces Fast Track
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K